Citations

Clear

371 citation(s) found for "Cho, B".

Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm.
Kumar, Shaji , Biran, Noa , Hultcrantz, Malin , Vij, Ravi , Ye, Jing Christine, Zonder, Jeffrey A. , DiLello, Lauren, Yesil, Jen, Bianchi, Giada , Richter, Joshua , Cho, Hearn Jay

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 8055-8055

10.1200/jco.2022.40.16_suppl.8055 Get It

8055 Background: Multiple myeloma (MM) is characterized by somatic mutations involving cancer-associated genes. The most commonly mutated genes are N- and K-Ras, which increase in prevalence as the disease progresses. Case reports and retrospective data suggest efficacy of targeting the MAPK pathway in N/K-Ras mutated MM. The MyDRUG trial was initiated to explore the efficacy of specific molecularly-targeted therapies in combination with standard therapies in MM. Methods: MyDRUG (NCT03732703) is a genomically-guided umbrella trial for patients with functional high-risk MM, defined as early relapse following primary therapy (3 years for transplant with maintenance, 18 months without), with specific genetic abnormalities. Subjects undergo molecular profiling of their MM cells and are assigned to a targeted arm if a variant allele frequency (VAF) over 25% is identified. The targeted mutated genes and respective agents (approved for non-MM indications and with a known phase 2 dose) are: KRAS/NRAS/BRAF (cobimetinib), FGFR3 (enasidenib), IDH (erdafitinib), CDKN2C (abemaciclib), t(11;14) (venetoclax). Patients receive the investigational drug for 2 cycles as a single agent followed by addition of an active MM combination (ixazomib, pomalidomide and dexamethasone, IPd). Limited dose escalation was performed with the single agent followed by dose assessment in combination with IPd. Here we present the results of the dose escalation portion of C1 arm exploring cobimetinib in patients with N/K-RAS or BRAF mutations. Cobimetinib was administered at 40 mg daily in combination with standard doses of IPd. Results: Eleven subjects with BRAF/RAS mutations were screened between August 2019 and October 2020, with 4 screen failures. Seven were enrolled, 5 males, median age 65 years, and median time from diagnosis of 30 months. N-RAS, K-RAS or BRAF mutations were seen in 4, 2, and 1 subject(s), respectively, with VAF ranging from 33-93%. Median number of prior lines of therapy was 1 (1-3), 3 patients had extramedullary disease, and 1 patient had high risk cytogenetics. Median duration of therapy was 12 months. One patient was not evaluable for dose limiting toxicity. All but 1 patient had at least one cycle delayed due to adverse events (AEs), but no dose reductions were required. No dose limiting toxicities were observed across the cycles, either during single agent therapy (Cycles 1-2) or in combination with IPd (Cycles 3 and 4). Six patients responded to therapy (4 PR, 2 VGPR). One patient was not response evaluable. Fatigue was the most common non-hematological AE followed by diarrhea. Conclusions: Here we report on the feasibility of genomically-guided, precision medicine therapy in K/N-RAS/BRAF-mutated MM. The MEK inhibitor cobimetinib in combination with IPd appears safe in functionally high-risk patients. Ongoing study will provide more information regarding the efficacy of this approach. Clinical trial information: NCT03732703.
Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).
Pei, Qinglin , McCarten, Kathleen M. , Punnett, Angela , Dave, Hema Kishore, Wu, Yue , Henderson, Tara O. , Keller, Frank G. , Kelly, Kara M. , Castellino, Sharon M. , Parsons, Susan K. , Hodgson, David , Horton, Terzah M. , Cho, Steve Y. , Hoppe, Bradford S.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 7504-7504

10.1200/jco.2022.40.16_suppl.7504 Get It

7504 Background: The anti-CD30 antibody drug conjugate, Brentuximab vedotin (Bv) is approved for adults with advanced stage HL but its use has not been established in children or adolescents. We compared the efficacy and safety of Bv with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (Bv-AVE-PC) to the standard pediatric dose intensive regimen ABVE-PC, inclusive of bleomycin. Methods: This multicenter randomized, open-label phase 3 study enrolled patients 2-21 years (yrs) with previously untreated HL, stages IIB + bulk, IIIB, IVA, IVB. Patients were randomized to 5 cycles of either ABVE-PC or Bv-AVE-PC given every 21 days with granulocyte colony-stimulating factor support. Centrally reviewed PET-CT after 2 cycles (PET2) identified slow responding lesions (SRL) defined as Deauville score > 3. Involved site radiotherapy (ISRT) was given to bulky mediastinal adenopathy and SRL. The primary objective was 3-year EFS; events include relapse/progression, second malignant neoplasm (SMN) or death. Final data cutoff was 31 December 2021. Results: 600 participants were enrolled across 151 institutions from March 2015 to August 2019; 587 were eligible. Median age was 15.6 yrs (range 3.4-21). Patient and disease characteristics were balanced across study arms. Histology was nodular sclerosing in 76.5%. Stage distribution: 20.6% IIB-bulk; 19.3% IIIB; 28.5% IVA; 31.7% IVB. At a median follow-up of 42.1 mos (0.1-80.9), 3-year EFS (95%CI) by intent-to-treat analyses was 82.5% (77.4, 86.5) with ABVE-PC and 92.1% (88.4, 94.7) with Bv-AVE-PC (HR 0.41 (0.25, 0.67), p = 0.0002). Median time to 1st event was 9.4 months for both arms but the range differs by arm (3.6-57.8 ABVE-PC; 1.3, 25.8 Bv-AVE-PC). Relapse rate was 17% following ABVE-PC and 7% with Bv-AVE-PC. One SMN is noted in each arm: thyroid cancer at 57.8 mos and acute myeloid leukemia at 20.3 mos. 3-year overall survival (95%CI) was 98.5% (96.0, 99.4) for ABVE-PC and 99.3% (97.3, 99.8) for Bv-AVE-PC (p = 0.38). PET2 SRL rates were comparable (ABVE-PC 19% vs. Bv-AVE-PC 18%, p = 0.8). As-treated ISRT receipt did not differ (ABVE-PC 55.7% vs. Bv-AVE-PC 52.7%, p = 0.69). No difference in grade 3/4 adverse events was observed; myelosuppression, reflected in a 32% incidence of > grade 3 febrile neutropenia, did not differ by arm (p = 0.67). Only 19% of patients experienced > grade 2 neuropathy by the Balis pediatric neuropathy scale, with no difference between arms (p = 0.86). Conclusions: Brentuximab vedotin with AVE-PC in a dose intensive regimen has superior efficacy to ABVE-PC for pediatric patients with high-risk HL. A 59% risk reduction in EFS was achieved with no increase in toxicity and with fewer patients receiving ISRT compared to prior pediatric trials for high-risk HL. Clinical trial information: 02166463.
Phase I/II trial of BMS-986205 and nivolumab as first line therapy in hepatocellular carcinoma.
Huynh, Jasmine , Cho, May Thet, Tam, Kit , Singh, Amisha , Naderi, Sima, Lamba, Ramit, McGahan, John P. , Loehfelm, Thomas W. , Navarro, Shannon M. , Lara, Frances, Martinez, Anthony, Garcia, Leslie, Kim, Edward , Cho, May , Monjazeb, Arta Monir , Fananapazir, Ghaneh , STEWART, SUSAN LEROY , Martinez, Anthony

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e16200-e16200

10.1200/jco.2022.40.16_suppl.e16200 Get It

e16200 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme expressed by HCC which helps to orchestrate immune suppression within the tumor microenvironment (TME) and may contribute to primary and acquired resistance of PD-(L)1 inhibitors. BMS-986205 is a novel oral drug that potently and selectively inhibits IDO1. This Phase I/II study is evaluating the safety and tolerability of the combination of BMS-986205 and nivolumab as first-line therapy in HCC. Methods: Patients (pts) ≥18y with untreated, unresectable/metastatic HCC received BMS-986205 in combination with nivolumab. A fixed dose of Nivolumab 240mg/m2 IV was administered on Day 1 of each 14-day cycle. BMS-986205 was an oral tablet administered daily; a total of two dose levels (50-100mg) were given to determine dose limiting toxicities (DLT) during the dose-escalation Phase I of the study. Safety was assessed using CTCAE v5.0 criteria, and efficacy was assessed by objective response rate (ORR) using RECIST v1.1 criteria. Secondary objectives included preliminary data on disease control rate (DCR), duration of response (DOR), ORR using immune RECIST criteria (iRECIST), progression free survival (PFS) and overall survival (OS). Results: Here we report the results of the dose escalation cohort. Eight pts were treated with median age 69y [60-76]; 75% male; and PS 0 (3 pts) or 1 (5 pts). Pts were White (62.5%), Asian (25%), and African American (12.5%). Six of 8 pts had underlying viral hepatitis (5 hepatitis C, 1 hepatitis B), and all pts were Child Pugh A at enrollment with median baseline alpha-fetoprotein (AFP) level 41.8 [3.8–917.2]; 4 pts received prior local therapies. A total of 91 cycles of therapy were administered; 2 pts received 27 and 43 cycles of treatment each. Six pts were evaluable for DLT; 2 pts were replaced for DLT assessment due to insufficient dose administered, unrelated to toxicity. No DLTs were observed at either the 50 or 100mg dose of BMS-986205. There were 24 treatment-related adverse events (TRAEs), 4 of which were Grade 3 events; there were no Grade 4-5 events. The most common TRAEs of all grades were AST elevation and ALT elevation in 3 pts, and diarrhea, maculopapular rash and increased alkaline phosphatase in 2 pts each. Grade 3 events were diarrhea and AST elevation (1 pt), and hyperglycemia and pancreatitis requiring treatment discontinuation (1 pt). Eight pts were evaluable for efficacy with best response of partial response in 1 pt (12.5%) and stable disease in 3 pts (37.5%), yielding a DCR of 50%. Median PFS was 8.5 weeks; median OS has not been reached. Conclusions: Combination BMS-986205 and nivolumab showed a manageable safety profile with durable benefit as 1st line therapy in a meaningful subset of patients with unresectable/metastatic HCC. Clinical trial information: NCT03695250.
A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed
Botrus, Gehan , Hecht, J. Randolph , Kasi, Anup , Pant, Shubham , Michelson, Glenn, Cho, Gene , Cho, Sangsook Ahn, Liganor, Lorna, Ko, Andrew H. , Walker, Evan Justin , Borazanci, Erkut , Fountzilas, Christos , Mettu, Niharika B , Pant, Shubham

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS4181-TPS4181

10.1200/jco.2022.40.16_suppl.tps4181 Get It

TPS4181 Background: The mainstay of treatment (TX) for pts with advanced or mPDAC consists of CT, with FOLFIRINOX and gemcitabine (gem)/nab-paclitaxel currently representing the front-line standards of care. TX is generally continued until either dis progression (progr) or cumulative toxicity, with pts often reaching a plateau in response after 4-6 mos. For those who have achieved dis control (stable dis or better) on front-line CT, a maint TX strategy that can effectively delay dis progr while preserving quality of life with minimal cumulative toxicity is highly desirable. However, aside from PARP inhibition in the subset of PDAC pts with gBRCA mutated dis, there is no current standard of care in this maint setting. Ival is a pan-HDAC (histone deacetylation) inhibitor that increases histone acetylation (HA), suppresses PDAC cell proliferation, and promotes apoptosis in PDAC cell lines in a dose-dependent manner. It has demonstrated synergy with 5-FU in cholangiocarcinoma cell lines and shows promising antitumor activity when combined with cap in syngeneic PDAC mouse models. On these bases, we are conducting a ph1b/randomized ph2 trial of ival plus cap vs cap alone in the maint setting for pts with mPDAC who have not progressed on front-line FOLFIRINOX. Methods: Key eligibility criteria include pts with mPDAC; no evidence of dis progr following at least 16 wks of front-line FOLFIRINOX at full or modified doses; ECOG PS 0-1; and no known gBRCA1/2 mutation. The study includes an initial dose-esc ph1b evaluating 3 dose levels of ival, (60, 125, and 250mg/m2 iv weekly on days 1 and 8) in combination (comb) with cap (1000mg/m2 po BID on days 1-14) of a 21-day cycle, using a standard 3 + 3 dose-esc design. Of note, ival 250 mg/m2 represents the RP2D identified in prior clinical studies of this agent both as monotherapy in solid tumors and in comb with gem/erlotinib in advanced PDAC pts. In the ph2 portion, pts will be randomized 1:1 to receive either ival plus cap or cap alone, in 21-day cycles, until dis progr, with tumor assessments occurring at 6-wk intervals. Blood will be collected at pre-specified serial timepoints for pharmacodynamic assessments, including HA of PBMCs. Primary endpoint for ph2 is investigator-adjudicated PFS. The primary analysis will compare PFS distributions in the ival/cap and cap alone arms using a one-sided log rank test with an alpha = 0.10. The assumed true 6-mo PFS rates are 35% (cap), based on historic data, and 60% (ival/cap), which corresponds to an HR of 0.487. Assuming an accrual duration of 18 mos and a dropout/lost to follow-up rate of 10%, the estimated total number of pts in the randomized ph2 portion is 52 (26 per arm). Enrollment is expected to being in spring 2022 across 25 U.S. sites.
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies, Faith E. , Pawlyn, Charlotte , Usmani, Saad Z. , Miguel, Jesús F. San , Boyle, Eileen M. , Corre, Jill , Auclair, Daniel , Cho, Hearn Jay , Sonneveld, Pieter , Stewart, A. Keith , Bergsagel, P. Leif , Kaiser, Martin , Morgan, Kathryn E., Ghobrial, Irene M. , Orlowski, Robert Z. , Caers, Joseph, Chari, Ajai , Walker, Brian A. , Kumar, Shaji , Costa, Luciano J. , Bergsagel, P. Leif , San-Miguel, Jesus , Boyle, Eileen M , Corre, Jill , Cho, Hearn Jay , Kaiser, Martin F , Keats, Jonathan J , Mikhael, Joseph R , Orlowski, Robert Z. , Landgren, C Ola , Gay, Francesca , Chng, Wee Joo , Chari, Ajai , Walker, Brian A , Kumar, Shaji K , Costa, Luciano J , Anderson, Kenneth C , Morgan, Gareth J , Davies, Faith E , Ghobrial, Irene M , Pawlyn, Charlotte , Usmani, Saad , Einsele, Hermann , Lonial, Sagar , Weisel, Katja C , Keats, Jonathan J. , Mıkhael, Joseph , Landgren, Ola , Gay, Francesca , Chng, Wee Joo , Anderson, Kenneth C. , Morgan, Gareth J.

Mayo Clinic

Blood Cancer Discovery | June 2, 2022 | Volume: 3 | Issue: 4 | Pages: 273-284

10.1158/2643-3230.bcd-21-0205 | PMID 35653112 Get It

Summary: The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study
Kim, Soungmun, Jeong, Seogsong , Park, Sun Jae , Chang, Jooyoung , Choi, Seulggie , Cho, Yoosun , Ahn, Joseph , Lee, Gyeongsil , Son, Joung Sik , Ahn, Joseph C , Chang, Jooyoung , Park, Sang Min

Mayo Clinic

Journal of Clinical Medicine | May 19, 2022 | Volume: 11 | Issue: 10 | Pages: 2865

10.3390/jcm11102865 | PMID 35628991 Get It

(1) Background: The association between proton pump inhibitor (PPI) use and hepatocellular carcinoma (HCC) has been controversial, especially in the general population. We aimed to determine the impact of PPI on HCC risk in participants without liver cirrhosis or chronic hepatitis virus infection. (2) Methods: We assessed 406,057 participants from the Korean National Health Insurance Service database who underwent health screening from 2003 to 2006. We evaluated exposure to PPI before the index date using a standardized daily defined dose (DDD) system. The association of proton pump inhibitor use with the risk of HCC was evaluated using multivariable-adjusted Cox proportional hazards regression. (3) Results: Compared with non-users, PPI use was not associated with the HCC risk in low (<30 DDDs; aHR, 1.07; 95% CI, 0.91–1.27), intermediate (30 ≤ PPI < 60 DDDs; aHR, 0.96; 95% CI, 0.73–1.26), and high (≥60 DDDs; aHR, 0.86; 95% CI, 0.63–1.17) PPI groups in the final adjustment model. In addition, risks of cirrhosis-associated HCC and non-cirrhosis-associated HCC were not significantly associated with PPI use. The results remained consistent after excluding events that occurred within 1, 2, and 3 years to exclude pre-existing conditions that may be associated with the development of HCC. We also found no PPI-associated increase in HCC risk among the selected population, such as those with obesity, older age, and chronic liver diseases. (4) Conclusions: PPI use may not be associated with HCC risk regardless of the amount. We call for future studies conducted in other regions to generalize our findings.
Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders
Mo, Heejung , Chung, Soo Jie , Rozen, Todd D. , Cho, Soo‐Jin

Mayo Clinic

Journal of Clinical Neurology | May 18, 2022 | Volume: 18 | Issue: 3 | Pages: 271

10.3988/jcn.2022.18.3.271 | PMID 35589316 Get It

Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles
Eekhoff, Elisabeth M. W. , Ruiter, Ruben D. de , Smilde, Bernard J. , Schoenmaker, Ton , Netelenbos, Coen , Scott, Christiaan , Haga, Nobuhiko , Grunwald, Zvi, Cunto, Carmen L. De, Rocco, Maja Di , Delai, Patricia , Diecidue, Robert J. , Morhart, Rolf, Friedman, Clive, Zasloff, Michael , Shim, Jae‐Hyuck , Gao, Guangping , Pignolo, Robert J. , Micha, Dimitra , Shim, Jae-Hyuck , Vries, Teun J. de , Hsiao, Edward C. , Cunto, Carmen De , Madhuri, Vrisha , Cho, Tae‐Joon , Pals, Gerard , Kaplan, Frederick S.

Mayo Clinic

Human Gene Therapy | May 3, 2022 | Volume: 33 | Issue: 15-16 | Pages: 782-788

10.1089/hum.2022.023 | PMID 35502479 Get It

Fibrodysplasia ossificans progressiva (FOP) is a rare and devastating genetic disease, in which soft connective tissue is converted into heterotopic bone through an endochondral ossification process. Patients succumb early as they gradually become trapped in a second skeleton of heterotopic bone. Although the underlying genetic defect is long known, the inherent complexity of the disease has hindered the discovery of effective preventions and treatments. New developments in the gene therapy field have motivated its consideration as an attractive therapeutic option for FOP. However, the immune system's role in FOP activation and the as-yet unknown primary causative cell, are crucial issues which must be taken into account in the therapy design. While gene therapy offers a potential therapeutic solution, more knowledge about FOP is needed to enable its optimal and safe application.
Genetic Regulators of Sputum Mucin Concentration Revealed by GWAS and Their Associations with Chronic Bronchitis and Acute Exacerbations of COPD
Radicioni, Giorgia , Garudadri, S., Curtis, J.L., Krishnan, J.A., Wan, E.S., Silverman, Edwin K. , Hastie, Annette T. , Ortega, Victor E. , Christenson, S., Li, Yingying , Cho, M.H., Kelada, Samir N. P. , Buren, Eric C. Van , O’Neal, Wanda K. , Dang, Hong , Kasela, Silva , Curtis, J.L., Han, MeiLan King , Lappalainen, Tuuli , Li, Y., Cho, M.H. , Kesımer, Mehmet

Mayo Clinic

C66. COPD: GENETICS, GENOMICS, AND EPIGENETICS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4666-A4666

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4666 Get It

A Metabolomic Severity Score for Airflow Obstruction and Emphysema
Godbole, Suneeta , Pratte, Katherine , Hill, Andrew , Hastie, Annette T. , Peters, Stephen P. , Gregory, Andrew , Ortega, Victor E. , DeMeo, Dawn L. , Bhatt, Surya P. , Wells, J. Michael , Barjaktarević, Igor , Stringer, Kathleen A. , Comellas, Alejandro P. , O’Neal, Wanda K. , Kechris, Katerina , Hill, Andrew , Gregory, Andrew , Barjaktarevic, Igor , Stringer, Kathleen A , Kechris, Katerina , O'Neal, Wanda K , Comellas, Alejandro P , Bhatt, Surya P , Wells, J Michael , Labaki, Wassim W. , Moll, Matthew , Cho, Michael H. , Bowler, Russell P.

Mayo Clinic

Metabolites | April 19, 2022 | Volume: 12 | Issue: 5 | Pages: 368

10.3390/metabo12050368 | PMID 35629872 Get It

Chronic obstructive pulmonary disease (COPD) is a disease with marked metabolic disturbance. Previous studies have shown the association between single metabolites and lung function for COPD, but whether a combination of metabolites could predict phenotype is unknown. We developed metabolomic severity scores using plasma metabolomics from the Metabolon platform from two US cohorts of ever-smokers: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) (n = 648; training/testing cohort; 72% non-Hispanic, white; average age 63 years) and the COPDGene Study (n = 1120; validation cohort; 92% non-Hispanic, white; average age 67 years). Separate adaptive LASSO (adaLASSO) models were used to model forced expiratory volume at one second (FEV1) and MESA-adjusted lung density using 762 metabolites common between studies. Metabolite coefficients selected by the adaLASSO procedure were used to create a metabolomic severity score (metSS) for each outcome. A total of 132 metabolites were selected to create a metSS for FEV1. The metSS-only models explained 64.8% and 31.7% of the variability in FEV1 in the training and validation cohorts, respectively. For MESA-adjusted lung density, 129 metabolites were selected, and metSS-only models explained 59.0% of the variability in the training cohort and 17.4% in the validation cohort. Regression models including both clinical covariates and the metSS explained more variability than either the clinical covariate or metSS-only models (53.4% vs. 46.4% and 31.6%) in the validation dataset. The metabolomic pathways for arginine biosynthesis; aminoacyl-tRNA biosynthesis; and glycine, serine, and threonine pathway were enriched by adaLASSO metabolites for FEV1. This is the first demonstration of a respiratory metabolomic severity score, which shows how a metSS can add explanation of variance to clinical predictors of FEV1 and MESA-adjusted lung density. The advantage of a comprehensive metSS is that it explains more disease than individual metabolites and can account for substantial collinearity among classes of metabolites. Future studies should be performed to determine whether metSSs are similar in younger, and more racially and ethnically diverse populations as well as whether a metabolomic severity score can predict disease development in individuals who do not yet have COPD.